Paolo Macchiarini is leaving Russia, his research and surgery stint there is over. The fallen star surgeon was able to find a professorship with the Federal University of Kazan (KFU), after his plastic trachea transplants at the Kuban State Medical University in Krasnodar left 3 patients dead, and one with a lucky escape (see details here). His new research focus was on artificial oesophagus, which he apparently already started to test on hapless baboons. In March 2017, the Russian state decided that Macchiarini’s federal grant on oesophagus research will not be renewed, the Kazan University announced in regard to their professor’s further employment to follow the instructions from the Russian Science Foundation. The professorship contract expires by December 2017. On April 20th, Kazan University made the official decision to shut down Macchiarini’s research programme. A Russian opposition party, Yabloko, demanded of the Ministry for Research and Education to investigate Macchiarini’s Megagrant funding and the use of that money, especially in view of the fact that no final report was published. All this information was revealed by the Russian health and medicine journalist Alla Astakhova on her website. Continue reading “Macchiarini leaves Russia: federal grant denied and Kazan lab shut down”
Trachea is a very difficult organ to transplant, because its blood supply happens through many tiny blood vessels and it is practically impossible to connect them all (same is true also for the oesophagus). An organ transplanted without blood supply will die, and this is where the regenerative medicine of Paolo Macchiarini and Martin Birchall comes in: a treatment with stem cells and growth factors will somehow magically ensure quick vascularization and bring the dead tissue to life. There is no independent evidence for this, and most patients died as the consequence or became dangerously ill when their new tracheas, made from plastic or from dead, decellurised cadaveric organs predictably failed. One boy has survived: Ciaran Lynch. His current clinical state is not too rosy, even by Birchall’s own admittance, but nevertheless the sole fact that Ciaran (unlike almost all other trachea transplant patients) is alive, sufficed for Birchall to have one or two more patients operated (both dead) and to push through a clinical trial in UK with a much larger follow-up trial EU-wide. The difference though: that boy never had much choice anyway, since he had no real trachea in the first place. He received very early on a pickled trachea homograft from dead human donor tissue which functioned very well for many years, but at some point urgently needed replacement in order to save his life. Now Birchall however wishes to remove the live airways of stable patients outside any life danger, who suffer from tracheal stenosis, and replace them with his regenerated dead ones (see this report). Noone seems to wonder why these tracheas are to be prepared in a radically different way from that of the sole success, Ciaran Lynch: Birchall’s bioreactor vs so-called “bionic” method of Macchiarini.
Today I stood my second injunction trial (previous here), and once again, the evidence was irrelevant. Today’s trial of Philipp Jungebluth against myself in the Berlin regional court was set for 30 minutes and this is also how long it took. The reason: the judge (and two co-judges) already made up their decision to uphold Jungebluth’s injunction against me (see story here and here), regardless of all evidence from my side about this doctor’s past. They were perfectly free to do so, because it was a speed trial, where (in theory) I was supposed to get my chance to finally defend myself after the very same judge passed that injunction without my prior knowledge or involvement, based on the claims submitted by Jungebluth. Such is the German law on press freedom, take it or leave the country. Also now, I didn’t get to say much, while Jungebluth and his lawyer were welcomed to explain their case to the court once again. My lawyer and I hardly got a chance to squeeze a word in. Continue reading “Judge in Jungebluth trial announces to uphold his injunction, dismisses all evidence”
Game over apparently near for the indestructible Swedish regenerative medicine researcher Suchitra Sumitran-Holgersson, after investigations at her University of Gothenburg draw to an end. It is about experimental transplants of decellurised veins “regenerated” with the patient’s own bone marrow cells into three child patients, all of whom ended up in life-long medical care, one patient received a liver transplant after her graft failed, another child suffered severe complications (see this earlier report about an external investigation by Bengt Gerdin into that matter). The University of Gothenburg then established an investigative committee, which followed up on the Gerdin report and specific concerns voiced by a journal editor and a colleague. I publish below the two decisions which revealed that Sumitran-Holgersson and her surgeon partner Michael Olausson never performed any animal testing before recruiting their human patients, they also failed to obtain ethics permits for these operations. Instead the two lied in their publications (Olausson et al, Lancet, 2012; Olausson et al EBioMedicine, 2014) about having obtained ethics votes (something I already uncovered before). During the investigation, Olausson and Sumitran-Holgersson were caught submitting false information to the committee. They were now found guilty of misconduct and ethics breach in both these publications. Continue reading “Sumitran-Holgersson and Olausson guilty of misconduct and unethical experiments on children”
On March 16th I stood a court trial by the trachea transplanters and University of Würzburg professors Heike and Thorsten Walles against myself. The judge (it was the same who passed the injunction against me) will announce his decision on April 6th, just as I will stand trial in Berlin against their trachea transplant colleague Philipp Jungebluth (see this report). I publish here an extended memory-based protocol which I first published on Facebook. Meanwhile, several large institutions built a protective wall of silence around Walles and their tracheal transplants. The German Medical Association refused investigation in a bizarre letter which I also publish below.
The court hearing
It was the so-called speed trial, so instead of examining evidence, everyone was free to tell the judge their views. Mostly, Walles and their lawyer spoke, occasionally, my lawyer and I were able to squeeze a word in to reject the outlandish or false claims. For example, while her lawyer insisted the tracheal transplants were full success despite dead patients, Heike Walles challenged me to compare her transplants with the first heart transplant which failed. I pointed out that this is exactly the same argument Paolo Macchiarini uses to defend his own failed trachea transplants (for example, here). Continue reading “Will words or actual evidence count in the Walles case?”
The misconduct-tainted paper on oesophagus transplants in rats (Sjöqvist et al 2014) by the fallen star of regenerative medicine Paolo Macchiarini is finally retracted by the journal Nature Communications. This happens after Swedish investigations found the authors (primarily the scandal thorax surgeon and his right-hand man Philipp Jungebluth) guilty of data manipulation and research misconduct in September 2016 and after the Karolinska Institutet (KI) shortly before Christmas publicly demanded a retraction (see my report here). Today’s retraction is a major setback for Macchiarini, since his current employment and funding at the Federal University of Kazan (KFU) in Russia depend on his experiments with oesophageal transplants in primates (see my reports here and here). That Russian project was in turn only possible because of Macchiarini’s allegedly successful experiments in rats, published in a prestige journal with “Nature” in its title. This paper’s retraction is therefore probably only the beginning of a whole looming avalanche of bad news for Macchiarini and his acolyte Jungebluth (who currently sues me in court). An expert review of their publication Jungebluth et al 2015 declares the findings of misconduct, ethics breach and patient abuse. The report however has yet to be confirmed by a commission at the Swedish Central Ethics Review Board (CEPN) and then formulated as an official decree by the KI. I publish the expert reviewer report below. Continue reading “Retraction, and another looming misconduct finding for Macchiarini and Jungebluth”
This is a new guest post from Johan Thyberg, a retired professor for cell and molecular biology from Sweden, a known activist against science fraud and author of the 2009 book “Scientific Fraud or Legal Scandal?”. Thyberg played a key role in uncovering the research misconduct and horrendous patient abuse around the trachea transplant surgeon Paolo Macchiarini, which took place at Alma Mater, the Karolinska Institutet (KI) in Stockholm, and left at KI alone 3 patients dead (his last plastic trachea recipient there, Yesim Cetir, died yesterday after years of suffering).
After a previous guest post by Thyberg, which criticised KI’s handling of the Macchiarini scandal, it is an honour for me to present his new article on my site. It deals with another international star of regenerative medicine whom KI recruited soon after Macchiarini: Kenneth Chien. The people who recruited Chien were also the same who made Macchiarini’s professorship at KI possible: the then-chancellor Harriet Wallberg and the cell biology professor Urban Lendahl. Both had to resign from their positions with the KI’s Nobel Committee in the wake of Macchiarini scandal (see my report here).
This is what Chien’s 20-head strong lab is working on at KI, according to its website:
“The central scientific interest of the Chien lab is to understand heart development at the molecular and cellular level, with the ultimate goal of applying the developmental principles, logic, pathways, technology, and model systems to unravel human heart disease”.
According to Thyberg, Chien’s engagement at KI is less about his actual scientific achievements, which seem objectively rather modest relative to his elite status there, but more about personal networks and money, which include pharma industry and a certain Chinese investor. One of these Chien-related businesses is Moderna Therapeutics, a biotech start-up which STAT News brought a critical special report on.
Below I am publishing Thyberg’s own English version article, a Swedish version appeared on March 17th on NewsVoice.